Department of Pharmacy, Hyogo Medical University Hospital, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Department of Respiratory Medicine and Hematology, Hyogo Medical University, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
Curr HIV Res. 2023;21(3):185-191. doi: 10.2174/1570162X21666230327165902.
Weight gain with the use of dolutegravir, bictegravir, and tenofovir alafenamide for antiretroviral therapy has been reported. However, studies on changes in body composition and the leptin/adiponectin ratio after antiretroviral therapy initiation are limited. These factors are important because they can be used as indicators of metabolic syndrome and cardiovascular disease risk.
This study aimed to investigate the changes in waist circumference, body composition, and adipokine levels after the initiation of antiretroviral therapy consisting of dolutegravir, bictegravir, and tenofovir alafenamide and evaluate the relationships between these parameters in Japanese patients living with human immunodeficiency virus.
This is a single-center, prospective, observational study. Waist circumference, body composition, and adipokine levels were measured at baseline and 12 months after antiretroviral therapy initiation in antiretroviral therapy-naive Japanese patients living with human immunodeficiency virus. Body composition was determined by bioelectrical impedance analysis.
We included 11 patients (10 bictegravir/TAF/emtricitabine, 1 dolutegravir/lamivudine) in this study. The results showed no significant changes in waist circumference and body composition among the patients. The leptin/adiponectin ratio and serum leptin levels significantly increased after antiretroviral therapy initiation. Changes in waist circumference, fat mass, and visceral fat area showed a strong positive correlation.
The leptin/adiponectin ratio increased following antiretroviral therapy initiation. The waist circumference measurement can be a simple, inexpensive, and useful method to identify changes in fat mass and visceral fat area after initiation of antiretroviral therapy.
已有报道称，使用多替拉韦、比克替拉韦和替诺福韦艾拉酚胺进行抗逆转录病毒治疗会导致体重增加。然而，关于抗逆转录病毒治疗开始后身体成分和瘦素/脂联素比值变化的研究有限。这些因素很重要，因为它们可以作为代谢综合征和心血管疾病风险的指标。
本研究旨在调查由多替拉韦、比克替拉韦和替诺福韦艾拉酚胺组成的抗逆转录病毒治疗开始后腰围、身体成分和脂肪因子水平的变化，并评估日本艾滋病毒感染者这些参数之间的关系。
这是一项单中心、前瞻性、观察性研究。在抗逆转录病毒治疗开始时和开始后 12 个月，对未接受过抗逆转录病毒治疗的日本艾滋病毒感染者测量腰围、身体成分和脂肪因子水平。身体成分通过生物电阻抗分析确定。
本研究共纳入 11 例患者（10 例比克替拉韦/TAF/恩曲他滨，1 例多替拉韦/拉米夫定）。结果显示，患者的腰围和身体成分没有明显变化。抗逆转录病毒治疗开始后，瘦素/脂联素比值和血清瘦素水平显著升高。腰围、脂肪量和内脏脂肪面积的变化呈强正相关。
抗逆转录病毒治疗开始后，瘦素/脂联素比值增加。腰围测量可以是一种简单、廉价且有用的方法，用于识别抗逆转录病毒治疗开始后脂肪量和内脏脂肪面积的变化。
